BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 23062898)

  • 1. Can the level of CD52 expression on Sézary cells be used to predict the response of Sézary syndrome to alemtuzumab?
    Fernandes IC; Gonçalves M; dos Anjos Teixeira M; Gonçalves C; Coutinho J; Selores M; Alves R; Lima M
    J Am Acad Dermatol; 2012 Nov; 67(5):1083-5. PubMed ID: 23062898
    [No Abstract]   [Full Text] [Related]  

  • 2. Pulmonary cryptococcoma in a patient with Sézary syndrome treated with alemtuzumab.
    Hotz C; Ingen-Housz-Oro S; Tran Van Nhieu J; Charlier C; Foulet F; Rahmouni A; Zegai B; Duong TA; Wolkenstein P; Bagot M; Chosidow O
    Eur J Dermatol; 2011; 21(6):1018-20. PubMed ID: 21926045
    [No Abstract]   [Full Text] [Related]  

  • 3. Alemtuzumab in Sézary syndrome: efficient but not innocent.
    Ure UB; Ar MC; Salihoglu A; Guner SI; Baran A; Oguz O; Ferhanoglu B
    Eur J Dermatol; 2007; 17(6):525-9. PubMed ID: 17951134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutation in PIGA results in a CD52-negative escape variant in a Sézary syndrome patient during alemtuzumab treatment.
    Halkes CJM; Zoutman WH; van der Fits L; Jedema I; Vermeer MH
    J Invest Dermatol; 2015 Apr; 135(4):1199-1202. PubMed ID: 25431852
    [No Abstract]   [Full Text] [Related]  

  • 5. Alemtuzumab in refractory Sézary syndrome.
    Reifs CM; Salido-Vallejo R; Garnacho-Saucedo GM; Corte-Sánchez S; González-Menchen A; García-Nieto AV
    An Bras Dermatol; 2016; 91(5):642-644. PubMed ID: 27828640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunophenotypic stability of Sézary cells by flow cytometry: usefulness of flow cytometry in assessing response to and guiding alemtuzumab therapy.
    Vaughan J; Harrington AM; Hari PN; Kroft SH; Olteanu H
    Am J Clin Pathol; 2012 Mar; 137(3):403-11. PubMed ID: 22338052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of FIP1L1/PDGFRA-negative hypereosinophilic syndrome with alemtuzumab, an anti-CD52 antibody.
    Wagner LA; Speckart S; Cutter B; Gleich GJ
    J Allergy Clin Immunol; 2009 Jun; 123(6):1407-8. PubMed ID: 19342084
    [No Abstract]   [Full Text] [Related]  

  • 8. Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center.
    Querfeld C; Mehta N; Rosen ST; Guitart J; Rademaker A; Gerami P; Kuzel TM
    Leuk Lymphoma; 2009 Dec; 50(12):1969-76. PubMed ID: 19860617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alemtuzumab treatment for Sézary syndrome: A single-center experience.
    Novelli S; García-Muret P; Sierra J; Briones J
    J Dermatolog Treat; 2016; 27(2):179-81. PubMed ID: 26329989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful treatment of chemotherapy-refractory Sézary syndrome with alemtuzumab (Campath-1H).
    Gautschi O; Blumenthal N; Streit M; Solenthaler M; Hunziker T; Zenhäusern R
    Eur J Haematol; 2004 Jan; 72(1):61-3. PubMed ID: 14962265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Sézary Syndrome With Alemtuzumab: A Series of 5 Cases and a Review of the Literature.
    del Alcázar-Viladomiu E; Tuneu-Valls A; López-Pestaña A; Vidal-Manceñido MJ
    Actas Dermosifiliogr; 2015 Sep; 106(7):e33-9. PubMed ID: 25960287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alemtuzumab-resistant Sézary syndrome responding to zanolimumab.
    Alexandroff AB; Shpadaruk V; Bamford WM; Kennedy DB; Burd R; Dyer MJ
    Br J Haematol; 2011 Aug; 154(3):419-21. PubMed ID: 21480857
    [No Abstract]   [Full Text] [Related]  

  • 13. Sezary syndrome presenting with leonine facies and treated with low-dose subcutaneous alemtuzumab.
    Oliveira A; Lobo I; Alves R; Lima M; Selores M
    Dermatol Online J; 2011 Nov; 17(11):6. PubMed ID: 22136862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents.
    Lapalombella R; Zhao X; Triantafillou G; Yu B; Jin Y; Lozanski G; Cheney C; Heerema N; Jarjoura D; Lehman A; Lee LJ; Marcucci G; Lee RJ; Caligiuri MA; Muthusamy N; Byrd JC
    Clin Cancer Res; 2008 Jan; 14(2):569-78. PubMed ID: 18223233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD52-Negative NK Cells Are Abundant in the Liver and Less Susceptible to Alemtuzumab Treatment.
    Hotta R; Ohira M; Matsuura T; Muraoka I; Tryphonopoulos P; Fan J; Tekin A; Selvaggi G; Levi D; Ruiz P; Ricordi C; Vianna R; Ohdan H; Waldmann H; Tzakis AG; Nishida S
    PLoS One; 2016; 11(8):e0161618. PubMed ID: 27560943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cutaneous hemophagocytosis after alemtuzumab injection in a patient with Sézary syndrome.
    Jawed SI; Busam K; Wang X; Horwitz S; Querfeld C
    JAMA Dermatol; 2014 Sep; 150(9):1021-3. PubMed ID: 25029560
    [No Abstract]   [Full Text] [Related]  

  • 17. Subcutaneous alemtuzumab for Sézary Syndrome in the very elderly.
    Alinari L; Geskin L; Grady T; Baiocchi RA; Bechtel MA; Porcu P
    Leuk Res; 2008 Aug; 32(8):1299-303. PubMed ID: 18096224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutrophils express CD52 and exhibit complement-mediated lysis in the presence of alemtuzumab.
    Ambrose LR; Morel AS; Warrens AN
    Blood; 2009 Oct; 114(14):3052-5. PubMed ID: 19638623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID mice.
    Carlo-Stella C; Guidetti A; Di Nicola M; Longoni P; Cleris L; Lavazza C; Milanesi M; Milani R; Carrabba M; Farina L; Formelli F; Gianni AM; Corradini P
    Exp Hematol; 2006 Jun; 34(6):721-7. PubMed ID: 16728276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Anomalous serological pattern of hepatitis B virus in 2 patients treated with alemtuzumab].
    García-Lozano T; Aznar-Oroval E; Guerrero-Zotano Á
    Rev Esp Quimioter; 2013 Sep; 26(3):228-9. PubMed ID: 24080890
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.